KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Abbott Laboratories (ABT) Short-Term Debt issuances (2016 - 2026)

Abbott Laboratories' Short-Term Debt issuances history spans 18 years, with the latest figure at $31.0 million for Q1 2026.

  • On a quarterly basis, Short-Term Debt issuances rose 186.11% to $31.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$48.0 million, a 433.33% decrease, with the full-year FY2025 number at -$115.0 million, down 15.0% from a year prior.
  • Short-Term Debt issuances hit $31.0 million in Q1 2026 for Abbott Laboratories, up from -$71.0 million in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for ABT hit a ceiling of $111.0 million in Q4 2023 and a floor of -$127.0 million in Q1 2024.
  • Historically, Short-Term Debt issuances has averaged -$6.8 million across 5 years, with a median of $8.0 million in 2022.
  • The widest YoY moves for Short-Term Debt issuances: up 1010.0% in 2023, down 625.0% in 2023.
  • Tracing ABT's Short-Term Debt issuances over 5 years: stood at $10.0 million in 2022, then soared by 1010.0% to $111.0 million in 2023, then crashed by 76.58% to $26.0 million in 2024, then plummeted by 373.08% to -$71.0 million in 2025, then soared by 143.66% to $31.0 million in 2026.
  • Business Quant data shows Short-Term Debt issuances for ABT at $31.0 million in Q1 2026, -$71.0 million in Q4 2025, and $8.0 million in Q3 2025.